Skip to main content

Table 11 Framingham risk score according clinical lipodystrophy and metabolic syndrome

From: Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

 

Without clinical lipodystrophy

With clinical lipodystrophy

Framingham risk score

Without MS

With MS

Total

Without MS

With MS

Total

Low risk (< 5%) [n (%)]

27 (45.8)

20 (29.4)

47 (37.0)

36 (41.9)

23 (21.5)

59 (30.6)

Average (5%-9%) [n (%)]

21 (35.6)

22 (32.4)

43 (33.9)

31 (36.0)

31 (29.0)

62 (32.1)

Moderate risk (10-19%) [n (%)]

7 (11.9)

13 (19.1)

20 (15.7)

15 (17.4)

31 (29.0)

46 (23.8)

High risk (20-39%) [n (%)]

3 (5.1)

12 (17.6)

15 (11.8)

2 (2.3)

20 (18.7)

22 (11.4)

Very high risk (> 40%) [n (%)]

1 (1.7)

1 (1.5)

2 (1.6)

2 (2.3)

2 (1.9)

4 (2.1)

p

0.078

< 0.001